Could a daily probiotic help protect aging brains?

NCT ID NCT06670807

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests whether a probiotic supplement taken daily for 16 weeks can improve cognitive function in older adults with mild cognitive impairment (MCI), a condition that raises the risk of dementia. One hundred participants aged 60 to 85 will be randomly assigned to receive either the probiotic or a placebo. Researchers will measure changes in brain activity, memory tests, and gut bacteria to see if the supplement offers any benefit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a probiotic dietary supplement called AB-MIND+CECT7481
What this could lead to
If it works, this could point toward a simple, safe way to slow or reverse early memory decline and reduce dementia risk.
What could go wrong
This is a small, early-stage trial with only 100 participants, and the effect on cognition may be modest or absent. Probiotics are generally safe but individual results can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women aged between 60 and 85 years. * Present "Mild Cognitive Impairment" (MCI) based on: * MoCA test (\< 26 points) or score adjusted for educational level * and CDR test (≤ 0.5 points) * Maintain functional capacity according to the (I)ADL test (≥ 70 points) * Show "cognitive concern" reported by the participant and/or a surrogate caregiver * Demonstrate longitudinal decline in cognitive function (progressive and not stabilized) for more than 3-5 years. * BMI ≥ 20 and \< 30 kg/m² * Absence of a family or social environment that prevents treatment adherence. * Adequate cultural level and understanding of the clinical study. * Agree to participate voluntarily in the study and provide written informed consent. Exclusion Criteria: * Subjects with severe neurological or psychiatric disorders due to any of the following causes: severe dementia, depression, epilepsy, schizophrenia, or bipolar disorder. * Subjects who have suffered a severe stroke prior to the study (FAZKAS=3) * Subjects with a history of malignancy \< 5 years (\< 5 years if the brain was affected) * Subjects who have experienced severe traumatic brain injury with structural brain injury and/or prior brain surgery * Subjects with pacemakers and those with metal implants that may interfere with EEG or MRI * Subjects treated with medications: benzodiazepines, neuroleptics, narcotics, anticonvulsants, or sedative-hypnotics in the last 3 months * Subjects who have been treated with antibiotics or probiotic supplements at least 3 months before the start of the study. * Subjects with hearing or visual impairments that prevent the evaluations included in the study * Subjects with severe illnesses affecting nutritional status (liver, kidney, etc.) * Subjects who have engaged in weight loss diets or significant dietary changes in the 8 weeks prior to starting the study * Subjects with high alcohol consumption (\> 3 alcoholic beverages per day)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mild cognitive impairment (MCI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Facultad de Farmacia Universidad Complutense de Madrid (UCM) Plaza Ramón y Cajal

    NOT_YET_RECRUITING

    Madrid, Madrid, 28040, Spain

  • Hospital Clínico San Carlos

    RECRUITING

    Madrid, Madrid, 28040, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.